Algernon Health Announces Effective Date of Previously Announced Name Change to "Grey Matters Health Inc." and its 10:1 Share Consolidation
Algernon Health Announces Proposed Name Change to "Grey Matters Health Inc." and a 10:1 Share Consolidation
Algernon Announces Additional Increase to Private Placement Financing to $858,000 and Final Closing of the Financing
Algernon Health and American Molecular Imaging Announce Strategic Business and USD $500K Investment Agreement
Algernon CEO and CSO to Discuss New DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
Algernon Pharmaceuticals Launches Stroke Treatment Clinical Research Program with Psychedelic Drug DMT "The Spirit Molecule"
Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19
Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment
Finlay Minerals Ltd. engages German Mining Networks and renews engagement with Investing News Network
LAURION Retains SMARTIR Marketing Ltd. to Drive Investor Awareness Ahead of Active 2026 Exploration Program
